Biz Brief: Mylan Reportedly Probed by SEC

Generic drugmaker Mylan (MYL) is being probed by the Securities and Exchange Commission over whether it shared confidential information about its third-quarter earnings with a few select investors before making it public, the Wall Street Journal reported, citing people familiar with the matter.

The SEC is said to have contacted several investment banks for details on an analyst meeting held in September 2009. The next day, the drugmaker's shares rose 7% on three times the previous month's average daily volume.

A company spokesman told the Journal, Mylan is "confident the communications made during the conference were entirely appropriate."

Mylan's third-quarter earnings released on Oct. 29 were better than expected and its shares rose 5%. The WSJ also quotes two UBS analyst reports that include comments such as: "given management's comments at the analyst meeting a month ago, expectations were high going into the quarter."
Read Full Story

Markets

NASDAQ 6,867.36 4.88 0.07%
S&P 500 2,597.08 -1.95 -0.07%
DJIA 23,526.18 -64.65 -0.27%
NIKKEI 225 22,550.85 27.70 0.12%
HANG SENG 29,866.32 158.38 0.53%
DAX 13,129.04 120.49 0.93%
USD (per EUR) 1.19 0.00 0.27%
USD (per CHF) 0.98 0.00 -0.07%
JPY (per USD) 111.36 0.11 0.10%
GBP (per USD) 1.33 0.00 0.16%

Can't get enough business news?

Sign up for Finance Report by AOL and get everything from retailer news to the latest IPOs delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.